Cartesian Therapeutics
RNAC
93 hedge funds and large institutions have $69.1M invested in Cartesian Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 15 closing their positions.
988% more call options, than puts
Call options by funds: $87K | Put options by funds: $8K
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
11% more funds holding
Funds holding: 84 → 93 (+9)
9% more capital invested
Capital invested by funds: $63.3M → $69.1M (+$5.8M)
0.19% less ownership
Funds ownership: 1.21% → 1.02% (-0.19%)
20% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.64M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.57M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.29M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$940K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$682K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$5.94M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.17M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$2.89M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.52M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$1.57M |
RNAC Hedge Fund Activity: Q1 2023 in Review
93 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2023, worth a combined $69.1M — up 9.2% from $63.3M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RNAC positions and 15 closed out — a net gain of 9 holders — while 20 added to existing stakes and 25 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $3.64M. The largest seller was Mangrove Partners, exiting entirely with an estimated $5.94M sold.
- 93 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2023, up from 84 in Q4 2022.
- Funds reported $69.1M of Cartesian Therapeutics stock for Q1 2023, up 9.2% quarter-over-quarter.
- 24 funds opened new Cartesian Therapeutics positions in Q1 2023 and 15 closed out, a net change of +9 holders.
- The largest Cartesian Therapeutics buyer in Q1 2023 was Sphera Funds Management, an estimated $3.64M added.
- The largest Cartesian Therapeutics seller in Q1 2023 was Mangrove Partners, an estimated $5.94M sold.
Based on aggregated 13F filings for Q1 2023.